Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IFx-Hu2.0 in Advanced Non-melanoma Skin Cancers
NCT04160065Phase 1Completed
- Sponsor
- TuHURA Biosciences, Inc.
- Start
- Mar 2020
- Primary completion
- Oct 2023
- Modality
- Gene Editing, Gene Silencing, Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of IFx-Hu2.0 in Merkel cell carcinoma (MCC) and cutaneous squamous cell carcinoma (cSCC), sponsored by TuHURA Biosciences, Inc. Primary endpoint: Number of Grade 3-5, Treatment-Related Adverse Events per CTCAE 5.0. Started Mar 2020; status: completed.
02
Drugs
IFx-Hu2.0
03
Conditions
Merkel cell carcinoma (MCC)cutaneous squamous cell carcinoma (cSCC)
Beyond the preview
Go deeper on NCT04160065.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04160065.